VHH antibody targeting the chemokine receptor CX3CR1 inhibits progression of atherosclerosis

Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody

(2015) Sanjaya Singh et al.   mAbs

Llama-derived Single Variable Domains (Nanobodies) Directed against Chemokine Receptor CXCR7 Reduce Head and Neck Cancer Cell Growthin Vivo

(2013) David Maussang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Substituted 7-Amino-5-thio-thiazolo[4,5-d]pyrimidines as Potent and Selective Antagonists of the Fractalkine Receptor (CX3CR1)

(2013) Sofia Karlström et al.   JOURNAL OF MEDICINAL CHEMISTRY

The Influence of Charge Distribution on Self-Association and Viscosity Behavior of Monoclonal Antibody Solutions

(2012) Sandeep Yadav et al.   MOLECULAR PHARMACEUTICS

Fractalkine Is Expressed in Early and Advanced Atherosclerotic Lesions and Supports Monocyte Recruitment via CX3CR1

(2012) Moritz Stolla et al.   PLoS One

Fractalkine/CX3CR1 and atherosclerosis

(2011) Hong Liu et al.   CLINICA CHIMICA ACTA

An engineered CX3CR1 antagonist endowed with anti-inflammatory activity

(2009) Karim Dorgham et al.   JOURNAL OF LEUKOCYTE BIOLOGY

CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival

(2008) L. Landsman et al.   BLOOD

When binding is enough: nonactivating antibody formats

(2008) Aran F Labrijn et al.   CURRENT OPINION IN IMMUNOLOGY

General Strategy to Humanize a Camelid Single-domain Antibody and Identification of a Universal Humanized Nanobody Scaffold

(2008) Cécile Vincke et al.   JOURNAL OF BIOLOGICAL CHEMISTRY